Setting an Agenda for Intermittent PrEP Research

May 19, 2010—Multiple clinical trials are taking place to determine whether giving antiretroviral therapy (ART) to HIV-negative people is an effective means of preventing infection. Most current trials of this potential new prevention strategy, known as pre-exposure prophylaxis (PrEP), involve a daily dose of ART. But researchers, advocates, and policy makers have also been exploring the question of whether intermittent use of PrEP (iPrEP) might be a viable and cost-effective alternative to taking medication every day.

In December 2009, amfAR and the AIDS Vaccine Advocacy Coalition convened a one-day meeting of leaders from the research community to review the status of iPrEP research, identify gaps, and suggest priorities for moving forward. In addition to reviewing current and planned PrEP studies, participants focused on how to evaluate the results of those studies in order to determine the best ways of delivering PrEP and to inform future research on PrEP and iPrEP.

To read the full report from the consultation, click here: Consultation on the Intermittent PrEP (iPrEP) Research Agenda (May 2010)